AKT activation, due to receptor tyrosine kinase transactivation, was shown to inhibit the FAS-associated factor 1 (FAF1)-mediated destabilization of the TGFβ receptor 2 (TβRII) in breast cancer cells. Here, FAF1 is linked to breast carcinoma.